Fundraisings and IPOs

* On July 8, 2013, Prosensa has announced the closing of its previously announced initial public offering of 6,900,000 of its ordinary shares at a price of $13.00 per share (including an additional 900,000 ordinary shares pursuant to the exercise of the over-allotment option by the underwriters). The ordinary shares began trading on the Nasdaq Global Market on June 28, 2013 under the symbol “RNA”.

* On June 27, 2013, Prosensa has announced the pricing of its initial public offering of 6,000,000 of its ordinary shares at an initial public offering price of $13.00 per share, before underwriting discounts. Prosensa has also granted the underwriters a 30-day option to purchase up to an additional 900,000 ordinary shares to cover over-allotments, if any. The ordinary shares are expected to begin trading on the Nasdaq Global Select Market on June 28, 2013 under the symbol “RNA.”

J.P. Morgan and Citigroup are acting as joint book-running managers for the offering. Leerink Swann is acting as lead manager, and Wedbush PacGrow Life Sciences, KBC Securities and Trout Capital are acting as co-managers.
* On May 28, 2013, Prosensa has announced that it has filed a registration statement on Friday May 24, 2013 on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its ordinary shares. The company intends to raise up to $60 million in an initial public offering. The number of shares to be offered and the price range for the offering have not been determined. J.P. Morgan and Citigroup are acting as joint book-running managers for the offering. Leerink Swann is acting as lead manager and Wedbush PacGrow Life Sciences and KBC Securities are acting as co-managers.